Prostate Cancer

Prostate cancer is the most common non-skin cancer in the United States and the third most common cancer worldwide. More than 1 million men in the United States have prostate cancer and it is the second leading cause of cancer death amongst men after lung cancer. In 2009, an estimated 192,280 new cases are expected to be diagnosed and approximately 27,360 men are expected to die from the disease. Castration-resistant prostate cancer (CRPC) is defined as prostate cancer that continues to grow despite all standard-of-care hormonal (anti-androgen) therapies. Patients with castration-resistant (also known as hormone-refractory) prostate cancer have few treatment options and a poor prognosis.

Prostate Cancer

Prostate cancer is one of the most common cancers in men, with more than 40,000 new cases diagnosed every year in the UK. This is usually a slow growing cancer and most men do not notice the symptoms until the cancer has become large enough to press against the urethra and interfere with urination.

The Prostate

Prostate Cancer Risk Factors

Prostate Cancer Screening

Prostate Cancer Symptoms

Prostate cancer complications

Prostate Cancer Diagnosis

Prostate Cancer Staging

Prostate Cancer Treatment

Radiation therapy for prostate cancer

Life after prostate cancer treatment

Prostate cancer prevention

See more featured articles »

Survival rates of prostate cancer

Precancerous conditions of the prostate

Prostate Cancer Questions

Prostate Cancer Epidemiology

Prostate Cancer Research

Prostate Cancer Partin Tables

Prostate Cancer and Genetics

Prostate Cancer and Diet

Rectal Examination for Prostate Cancer

Cryosurgery for prostate cancer

Hormonal therapy for prostate cancer

Prostate cancer alternative and complementary therapies

Palliative treatment and end of life care for prostate cancer

Vasectomy and prostate cancer: Myth or reality?

The International Prostate Symptoms Score (IPSS)

Types of PSA Test

What is the PSA Test?

Prostate Biopsy

PSA Test in Men Who Have Been Treated for Prostate Cancer

PSA False Positive and False Negative Results

Differentiating between prostate cancer and prostate enlargement

Choosing the best treatment of prostate cancer - by stage

What is the PCA3 Test?

What is the Gleason Score?

What is Prostatectomy?

What is Prostatitis?

Causes of prostatitis

Prostatitis symptoms

Diagnosis of prostatitis

Treatment of prostatitis

What is TURP?

What is medical castration?

What is benign prostatic hyperplasia?

Diagnosis of Benign Prostatic Hyperplasia (BPH)

Symptoms of Benign Prostatic Hyperplasia (BHP)

Causes of benign prostatic hyperplasia

Treatment of Benign Prostatic Hyperplasia (BHP)

Should MRI be Used to Diagnose Prostate Cancer?

Prostate Cancer and Exercise

Prostate Cancer Epidemiology Worldwide

Prostate Cancer Cell Dormancy and Activation

Single Nucleotide Polymorphisms and Prostate Cancer

Gallium Ga 68-labeled PSMA-11 PET/CT Imaging for Prostate Cancer

Can Curcumin Prevent or Treat Prostate Cancer?

Brachytherapy for Prostate Cancer

What Should You Avoid Before a PSA Test?

Latest Prostate Cancer News and Research

Empowering communities: Penn Medicine's annual mammogram event and health fair

Penn Medicine will once again join with community partners and Siemens Healthineers to host a free mammogram clinic and community health fair in June, giving the West Philadelphia and Upper Darby communities convenient access to health screenings right in their neighborhoods.

13 Jun 2024

First-in-human trial shows safety and efficacy of CAR T cell therapy for advanced prostate cancer

Treating prostate cancer with immunotherapy is currently difficult to do. But results from a first in-human phase 1 trial using a chimeric antigen receptor (CAR) T cell therapy developed by researchers from City of Hope, one of the largest cancer research and treatment organizations in the United States, showed that patients with advanced prostate cancer can be treated safely with the cellular immunotherapy with promising therapeutic activity, according to the phase 1 trial study published today in Nature Medicine.

12 Jun 2024

Revolutionary AI tool detects multiple cancers in whole-body PET/CT scans

A novel AI approach can accurately detect six different types of cancer on whole-body PET/CT scans, according to research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting.

11 Jun 2024

Innovative FAP-targeted radioligand therapy controls disease progression in sarcoma

Fibroblast activation protein (FAP)-targeted radioligand therapy is safe and effective for treating patients with progressive metastatic tumors, specifically advanced sarcomas, according to research presented at the 2024 Society of Nuclear Medicine and Molecular Imaging Annual Meeting.

10 Jun 2024

Glowing marker dye gives medics a 'second pair of eyes' during prostate cancer surgery

A glowing marker dye that sticks to prostate cancer cells could help surgeons to remove them in real-time, according to a study funded by Cancer Research UK.

10 Jun 2024

Unlocking the potential of ubiquitin-proteasome system in cancer treatment

A new editorial paper was published in Oncoscience (Volume 11) on May 6, 2024, entitled, "Restoring our ubiquitination machinery to overcome resistance in cancer therapy."

7 Jun 2024

JUN protein could slow prostate cancer growth, study finds

As prostate cancer progresses, it becomes increasingly aggressive and can metastasise. In this form, the tumor is difficult to treat, which is reflected in high mortality rates: Worldwide, the malignant disease of the prostate is the second most common cause of cancer death in men.

5 Jun 2024

Early menopause may increase risk for developing breast and ovarian cancer

Some women who experience menopause early-;before age 40-;have an increased risk for developing breast and ovarian cancer, according to research being presented Monday at ENDO 2024, the Endocrine Society's annual meeting in Boston, Mass.

3 Jun 2024

Experimental treatment for metastatic pancreatic cancer shows promise in phase 2 clinical trial

Clinicians at Georgetown University's Lombardi Comprehensive Cancer Center reported promising preliminary findings based on outcomes in the first six patients with metastatic pancreatic cancer enrolled in a phase 2 clinical trial of the experimental drug BXCL701 in combination with the immunotherapy drug pembrolizumab (Keytruda).

3 Jun 2024

Study reveals disparities in the delivery of cancer-related care at minority serving hospitals

It’s important to ensure that care provided at US hospitals that predominantly serve Black and Hispanic populations is as high-quality as the care provided at other US hospitals. New research reveals significant disparities in the delivery of cancer-related care at minority serving hospitals (MSHs) compared with non-MSHs, however.

3 Jun 2024

Integrating PGx testing for personalized prostate cancer treatment

Prostate cancer (PC) is a significant health concern, being the second leading cause of death among American men.

31 May 2024

Stress and pain linked to worse outcomes in HER2-positive breast cancer patients

Secondary analyses of a phase 3 clinical trial have revealed that breast cancer patients who reported high levels of pain and stress were more likely than their study peers to experience worse invasive disease-free survival (iDFS) and worse overall survival (OS).

31 May 2024

Polygenic risk score shows potential to predict survival outcomes in breast cancer patients

Data from a large prospective cohort study reveal that a polygenic risk score has the potential to predict survival outcomes in patients with breast cancer.

31 May 2024

COVID-19 associated with higher risk of erectile dysfunction

Men previously diagnosed with COVID-19 are at a greater risk of developing new-onset erectile dysfunction.

31 May 2024

Understanding the long-term effects and safety of testosterone therapy in transgender men

Transgender individuals often face unique challenges in aligning their physical bodies with their true gender identity.

30 May 2024

MUSC researchers unravel the mystery of cancer recurrence

MUSC Hollings Cancer Center researchers have unlocked a discovery that could help to explain why cancer can recur in patients who have undergone chemotherapy or radiotherapy.

28 May 2024

Underappreciated set of enzymes connected to the regulation of hippo pathway in cancer

Within the family of cell membrane lipids known as phosphoinositides and the kinase enzymes that regulate them, phosphoinositide 3-kinases (PI3Ks) have been cast in a starring role as scientists study their involvement in cancer, diabetes and many cellular activities.

28 May 2024

Study reveals cancer treatment disparities at minority-serving hospitals

It’s important to ensure that care provided at US hospitals that predominantly serve Black and Hispanic populations is as high-quality as the care provided at other US hospitals.

27 May 2024

$Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy$

Osaka University to pioneer world-first clinical trial for refractory prostate cancer with alpha-ray therapy

A research team at Osaka University will start an investigator-initiated clinical trial for refractory prostate cancer patients after the successful development of a new alpha-ray therapeutic agent ([At-211] PSMA-5) and confirmation of its efficacy in animal models.

27 May 2024

Physician-pharmacy integration not associated with change in the care of cancer patients

Integration of pharmacies with physician practices, where on-site pharmacies open at physician practice locations, is a growing trend in cancer treatment.

23 May 2024